INMB PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

INMB ▲ +16.87% at T+20d

NEUTRAL call ✓ call won +16.87% · α vs SPY +7.44% · entry $1.13 → $1.32

Next anchor: T+60d in 10d

Last close $1.24 (close Jun 12) · +9.73% from $1.13 entry

Entry anchored
Mar 30, 03:59 PM ET
via Databento tick

T+1d

+8.85%

call +8.85% · α +8.10%

$1.23

settled 3mo ago

T+5d

+14.16%

call +14.16% · α +10.22%

$1.29

settled 2mo ago

T+20d

+16.87%

call +16.87% · α +7.44%

$1.32

settled 7w ago

T+60d

—

call — · α —

—

in 10d

Price Chart

Loading chart...

Executive Summary

INmune Bio reported a net loss of $45.9 million for 2025, wider than the $42.1 million loss in 2024, driven by a $16.5 million impairment charge and reduced R&D spending. The company highlighted progress in its CORDStrom™ and XPro™ late-stage programs, with regulatory filings expected in 2026 and cash runway extending to Q1 2027. Despite advancing clinical assets, the increased loss and lack of revenue raise concerns about sustainability.

Key Financial Metrics

Revenue

$50.0K

EPS

$-1.86

Actionable Insight

The stock may react positively to the advancement of late-stage assets, particularly CORDStrom™ regulatory filings, but traders should monitor cash burn and upcoming financing risk as the company remains pre-revenue with limited near-term income potential.

Key Facts

Net loss for 2025 was $45.9 million vs. $42.1 million in 2024
Research and development expenses decreased to $20.7 million from $33.2 million
Impairment charge of $16.5 million related to in-process R&D in 2025
Cash and cash equivalents were $24.8 million as of December 31, 2025
Cash runway expected through Q1 2027
MAA for CORDStrom™ expected in UK mid-summer 2026, FDA BLA in Q4 2026
XPro™ advancing to Phase 2b/3 for Alzheimer’s with FDA alignment
No revenue in 2025, only $50K in total

Financial Impact

Increased net loss of $3.8 million YoY with a $16.5 million non-cash impairment; minimal revenue generation

net losscash positionR&D spendrevenue

Risk Factors

Continued losses and reliance on future financings
Clinical trial failure risk for CORDStrom™ and XPro™
Regulatory delays or rejections

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3264946

6 reports for INMB

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+20▲ +18.85%Mar 19, 2026

Filters

Reports for INMB — sortable, filterable
	Type				Now
Jun 2, 2026 12d ago	8-K BULLISH ★ 7/10	$1.32 $1.35	▲ +2.27%	▲ +1.87%	$1.24 (−6.06%)
May 7, 2026 5w ago	Press Release MIXED ★ 4/10	$1.43 $1.35	▼ −5.59%	▼ −5.83%	$1.24 (−13.29%)
May 5, 2026 5w ago	8-K NEUTRAL ★ 4/10	$1.52 $1.43	▼ −5.92%	▼ −5.59%	$1.24 (−18.42%)
Apr 30, 2026 6w ago	Press Release BEARISH ★ 6/10	$1.43 $1.51	▼ −5.59%	▼ −5.37%	$1.24 (+13.29%)
Mar 30, 2026 10w ago	Press Release MIXED ★ 6/10	$1.13 $1.23	▲ +8.85%	▲ +8.10%	$1.24 (+9.73%)
Mar 19, 2026 12w ago	Press Release BULLISH ★ 7/10	$1.22 $1.17	▼ −4.10%	▼ −2.36%	$1.24 (+1.64%)

US Market Status

Market Closed — Opens in 4h 44m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access